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Objective: Our objective was to analyze the relationship between
bone mineral density (BMD) changes and fracture incidence during
3-yr treatment with strontium ranelate.
Patients: Women from the strontium ranelate arm of the Spinal
Osteoporosis Therapeutic Intervention study and the TReatment Of
Peripheral OSteoporosis study were evaluated.
Outcome Measures: The outcome measures included BMD at the
lumbar spine, femoral neck, and total proximal femur assessed at
baseline and after a follow-up of 1 and 3 yr; semiquantitative visual
assessment of vertebral fractures; and nonvertebral fractures based
on written documentation.
Results: After 3 yr of strontium ranelate treatment, each percentage
point increase in femoral neck and total proximal femur BMD was
associatedwith a 3% (95%adjusted confidence interval, 1–5%) and 2%
(1–4%) reduction in risk of a new vertebral fracture, respectively. The
3-yr changes in femoral neck and total proximal femur BMD ex-
plained 76% and 74%, respectively, of the reduction in vertebral
fractures observed during the treatment. Three-year changes in spine
BMD were not statistically associated with the incidence of new ver-
tebral fracture (P  0.10). No significant associations were found
between 3-yr changes in BMD and incidence of new nonvertebral
fractures, but a trend was found for femoral neck BMD (P 0.09) and
for total proximal femur BMD (P 0.07). An increase in femoral neck
BMD after 1 yr was significantly associated with the reduction in
incidence of new vertebral fractures observed after 3 yr (P  0.04).
Conclusion: During 3-yr strontium ranelate treatment, an increase
in femoral neck BMDwas associated with a proportional reduction in
vertebral fracture incidence. (J Clin Endocrinol Metab 92:
3076–3081, 2007)
OSTEOPOROSIS IS A disease characterized by a de-crease in bone mass and deterioration in skeletal mi-
croarchitecture, leading to increased fragility and suscepti-
bility to fracture. It is now widely accepted that one of the
major determinants of skeletal weakness results from the
bone loss that occurs after the menopause. Epidemiological
studies of fracture incidence have shown that, in untreated
patients, low bone mineral density (BMD) is consistently
correlated with increased fracture risk (1–3).
Several randomized, controlled trials have demonstrated
that pharmacological agents improve BMD and reduce the
risk of fracture (4–10). However, the predictive value of BMD
changes for fracture risk reduction is highly controversial for
antiresorptive agents (11, 12). Although increases in BMD
resulting from various pharmacological treatments differ
widely, reported reductions in vertebral fracture risk are
rather similar (4–10). The relationship between changes in
BMD and fracture risk may be different because these agents
modify bone strength through different mechanisms of ac-
tion at the tissue level (i.e. improvement in bone quality
parameters) (13).
Strontium ranelate is composed of an organic moiety
(ranelic acid) and two atoms of stable (nonradioactive) stron-
tium. Although its molecular mechanism of action is not
totally elucidated, strontium ranelate has been shown, in
preclinical models, to reduce concomitantly bone resorption
and increase bone formation (14, 15). Strontium ranelate was
recently demonstrated to reduce significantly risk of verte-
bral (9), nonvertebral (10), and, in a high-risk population, hip
fracture risk in women with postmenopausal osteoporosis.
Moreover, significant increases in lumbar spine, femoral
neck, and total hip BMD have been consistently reported in
all populations exposed to strontium ranelate (9, 10, 16, 17).
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The relationship between measured, unadjusted BMD
changes and fracture incidence during long-term treatment
with strontium ranelate, however, is still unknown and is of
clinical interest because strontium is a bone-seeking agent
with a heavier atomic number than calcium, thus influencing
BMD measurements (18, 19). Correlation between the in-
crease in BMD and the reduction in fracture rates might also
be of interest for monitoring strontium ranelate-treated pa-
tients in daily practice.
The objective of this study was to analyze the association
between changes (1-yr and 3-yr) in BMD and vertebral and
nonvertebral fracture risk during 3-yr treatment with stron-
tium ranelate.
Patients and Methods
This post hoc analysis was performed on data from the SOTI (Spinal
Osteoporosis Therapeutic Intervention) and the TROPOS (TReatmentOf
Peripheral OSteoporosis) studies (9, 10). The design and methodology
of these two studies were fully described in previous reports (9, 10).
Briefly, postmenopausal outpatients were recruited in 11 European
countries and in Australia in two prospective, randomized, double-
blind, placebo-controlled trials, i.e. SOTI and TROPOS. Women were
eligible for the SOTI study if they were at least 50 yr old, had been
postmenopausal for at least 5 yr, had at least one prevalent vertebral
fracture confirmed by spinal radiography, and had a lumbar spine BMD
of 0.840 g/cm2 or less. In the TROPOS study, the criteria of eligibility
were a femoral neck BMD of 0.600 g/cm2 (corresponding with a
T-score  2.5), an age of 74 yr or older, or an age between 70 and 74
yr with at least one additional risk factor for fracture. These two studies
lasted 5 yr, with the main statistical analysis over 3 yr, and compared
2 g/d of strontium ranelate with placebo. Calcium and vitamin D sup-
plementation was prescribed throughout the studies with the dosage
determined during a run-in period. All participants gave written in-
formed consent before enrollment, and the appropriate institutional
review boards approved these two studies.
BMD was measured by dual energy x-ray absorptiometry (DXA) at
baseline and at 6-month intervals at the lumbar spine (region of interest
L2–L4) and proximal femur (Hologic Inc, Bedford, MA). All the scans
were analyzed centrally, and the femoral neck, total proximal femur, and
spine BMD T-scores were calculated according to the centralized Eu-
ropean normative data (D.O. Slosman, Geneva, Switzerland). A quality
control program including daily quality controls was conducted
throughout the studies (20). Coefficients of variation for in vivo DXA
measurements were 1.47% at the lumbar spine, 1.62% at the femoral
neck, and 1.24% at the total proximal femur.
Vertebral fractureswere assessed by the same team in a central facility
throughout the 3-yr studies (C. Roux and J. Fetchenbaum, Paris, France),
using a semiquantitative visual assessment of each vertebra, from T4 to
L4 (21) (L5 vertebra was assessed as fractured or not fractured) (21). The
semiquantitative grading scale was as follows: grade 0, normal; grade
1, a 20–25% decrease in the height of any vertebra; grade 2, a 25–40%
decrease; and grade 3, a decrease of 40% or more. A new fracture was
defined by a change in the score of a vertebra from grade 0 to grade 1
or more. A clinical vertebral fracture was defined as a new fracture
(semiquantitative assessment) with either the presence of back pain or
a body height loss of at least 1 cm.
During the study, nonvertebral fractures were reported by study
investigators based on written documentation provided and docu-
mented in the source document (radiograph, radiological report, copy
of the hospitalization/emergency department report). Only docu-
mented nonvertebral fractures were taken into account in the statistical
analysis. Fractures of the coccyx, skull, jaw, face, phalanx (fingers and
toes), and ankle were not regarded as being related to osteoporosis and
were not considered.
Statistical analysis
Patients were included in this particular analysis only if they had
vertebral x-rays and spine BMDperformed at baseline and after 1 yr and
3 yr, independent of drug compliance. A total of 3640 patients (1813 from
the strontium ranelate group and 1827 from theplacebo group)met these
inclusion criteria. Out of these 3640 patients, 1100 were in the SOTI trial
and 2540 in the TROPOS trial. The association between changes in BMD
and fracture incidence (vertebral and nonvertebral) was assessed only
in the strontium ranelate-treated patients through a logistic regression
analysis with age, body mass index, number of prevalent vertebral
fractures, and baseline BMD as covariates. The Mann-Whitney test was
used to compare the changes in BMD after strontium ranelate treatment
in patients with and without new fractures. We also assessed the risk of
sustaining at least one new fracture in different groups stratified for
different BMD changes (i.e. or 3% of BMD change), after controlling
for covariates.We also performed the analysis with the absolute changes
in BMD, using the individual smallest detectable difference as a refer-
ence (22). The proportion of treatment effect explained by BMD changes
was assessed from logistic regression models that included, besides the
effects for treatment and end points, fixed effects for age, body mass
index, BMD, and number of prevalent vertebral osteoporotic fractures
at the start of follow-up. The proportion was computed as the ratio of
the risk reduction explained by the surrogate alone over the overall risk
reduction by treatment and surrogate (23).
Results
Baseline characteristics of this study population are pre-
sented in Table 1. In patients treatedwith strontium ranelate,
a 3-yr increase in femoral neck and total proximal femur
BMD was statistically associated with a reduction in the
incidence of newvertebral fractures (P 0.001 andP 0.008,
respectively). Changes in spine BMD were not statistically
associated with the incidence of vertebral fracture (P 0.10).
For each percentage point increase in femoral neck or total
proximal femur BMD observed after 3 yr, the risk of sus-
taining a new vertebral fracture after 3 yr decreased by 3%
[95% adjusted confidence interval (CI), 1–5%] and 2% (1–
4%), respectively. Figure 1 shows the relationship between
vertebral fracture rate and total proximal femur BMD
changes in the placebo and strontium ranelate groups. The
results did not substantially change when clinical vertebral
fractures were considered, i.e. 5% (2–7%) and 4% (2–6%)
decreases in risk were observed for each percentage point
increase after 3 yr in femoral neck and total proximal femur
BMD, respectively.
Using the method developed by Li et al. (23), the changes
in total proximal femur and femoral neck BMD explained
74% and 76%, respectively, of the vertebral antifracture ef-
ficacy of strontium ranelate.
On average, patients sustaining new vertebral fractures
over 3 yr gain less femoral neck BMD (mean [sd]) (4.5%
[9.1]) than patients without vertebral fractures (5.7% [7.4])
TABLE 1. Baseline characteristics of the strontium ranelate
group included in this study (n  1813)
Variables Mean Median SD
Age (yr) 73.3 73.0 6.0
Body mass index (kg/m²) 25.9 25.6 4.0
BMD (g/cm²)
Lumbar spine 0.774 0.764 0.147
Total hip 0.674 0.674 0.095
Femoral neck 0.574 0.574 0.072
BMD (T-score)
Lumbar spine 3.06 3.17 1.53
Total hip 2.48 2.48 0.94
Femoral neck 2.96 2.94 0.63
No. of previous vertebral fractures 1.19 0 1.92
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(P  0.03 between the two groups). When considering clin-
ical vertebral fractures, patients with new fractures experi-
enced less gain in femoral neck BMD (3.6% [9.4]) than
patients without fractures (5.7% [7.5]) (P 0.009 between the
two groups).
Strontium ranelate-treated patients experiencing an in-
crease in femoral neck or total proximal femur BMD (0%)
after 3-yr treatment have a lower vertebral fracture incidence,
compared with similarly treated patients who lose BMD
(Table 2). After controlling for covariates, patients with an
improvement of at least 3% in femoral neck BMD were at a
lower risk of sustaining new vertebral fractures (odds ratio
0.62 [0.42–0.81]) than patients without such improvement.
The results were in the same range when considering
changes in total proximal femur BMD (odds ratio 0.63 [0.49–
0.86]). The risk of sustaining new clinical vertebral fractures
in patients in the highest quartile of femoral neck BMD
change (9.49%) was reduced by 41% (P  0.02) compared
with patients in the lowest quartiles (1.01%).
Of the patients treated with strontium ranelate, 45.7% ex-
perienced an absolute gain of 0.033 g/cm2 in femoral neck
BMD after 3-yr treatment, corresponding with the smallest
detectable difference in femoral neck BMD measurement.
The risk of a new vertebral fracture in these patients was
reduced by 24% (2–41%) (P 0.03), compared with patients
without such gain in BMD. Similarly, 58.2% of the patients
experienced an increase in total proximal femur BMD, the
smallest detectable difference of 0.038 g/cm2. The risk of a
new vertebral fracture in these patients was reduced by 34%
(15–48%) (P  0.001), compared with patients without this
BMD increase.
No significant associations were found between 3-yr
change in spine BMD and incidence of new nonvertebral
fractures (P  0.21), but a trend was found for femoral neck
BMD (P 0.09) and for total proximal femur BMD (P 0.07).
When considering the changes in BMD observed after 1 yr
of strontium ranelate, the logistic regression analysis includ-
ing age, body mass index, prevalence of vertebral fractures,
and baseline BMD as covariates showed that 1-yr increases
in femoral neck BMD were associated with the reduction in
incidence of new vertebral fractures observed over 3 yr (P
0.04). However, 1-yr increases in total proximal femur and
lumbar BMD were not significantly associated with the re-
duction in vertebral fractures (P  0.06 and P  0.18, re-
spectively). For each percentage point increase in femoral
neck BMD after 1 yr, the incidence of a new clinical vertebral
fracture after 3 yr decreased by 3% (95% CI, 1–6%). The
reduction was of similar magnitude [3% (95% CI, 1–5%); P
0.04] for clinical vertebral fractures. Patients experiencing an
increase in femoral neck BMD (0%) after 1 yr had a 21%
reduction (95% CI, 1–37%) (P  0.04) in the risk of a new
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FIG. 1. Logistic regression analysis
curves (95% CI) of the percentage
changes in femoral neck BMD at 3 yr
and the new vertebral fractures rates at
3 yr in the placebo and strontium rane-
late groups.
TABLE 2. Incidence of new vertebral fractures stratified for patients with and without 3-yr increases in femoral neck or total proximal
femur BMD










(n  1528) P
Relative risk
(95% CI)
Vertebral fractures 17.2% 11.4% 0.003 0.66 (0.51–0.87) 21.7% 11.1% 0.0001 0.51 (0.39–0.67)
Clinical vertebral fractures 10.9% 6.1% 0.001 0.56 (0.39–0.80) 14.6% 5.8% 0.0001 0.40 (0.28–0.57)
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vertebral fracture over 3 yr, compared with patients without
increase in BMD.
In strontium ranelate-treated patients, no significant as-
sociations were found between the 1-yr change in BMD and
the incidence of new nonvertebral fractures (P  0.63 for
spine BMD, P 0.18 for femoral neck BMD, and 0.41 for total
proximal femur BMD).
Discussion
We have demonstrated an association between vertebral
fracture incidence and changes in total proximal femur BMD,
as well as femoral neck BMD, in patients treated with stron-
tium ranelate for 3 yr. Applying the methodology recently
used for antiresorptive agents (11, 24), we calculated that,
during 3-yr treatment with strontium ranelate, the change in
total proximal femur BMD or femoral neck BMD explained
more than 70% of the vertebral fracture risk reduction .
These observations of an association between BMD
changes and fracture risk are supported by preclinical stud-
ies. Indeed, there is a robust correlation between the increase
in BMD during strontium ranelate treatment and improve-
ment in biomechanical properties of the vertebral and upper
femoral extremity in intact female rats (15).
We found no association between lumbar BMD changes
and vertebral fracture incidence during the 3-yr treatment.
Theoretically, based on greater spine BMD changes observed
after 3-yr treatment and better lumbar spine precision error
(compared with femoral neck), it should be easier to show
associations between BMD and vertebral fracture using spi-
nal BMD measurements than using femoral neck. Indeed,
some studies have found a significant association between
spine BMD changes and vertebral fracture incidence (25, 26).
However, with age, the presence or worsening of degener-
ative conditions of the spine, such as osteophytes and end-
plate sclerosis, contribute to the variation in lumbar spine
BMD measurement (27). Moreover, microarchitectural de-
formities in the vertebra may accumulate over time and
contribute to the apparent increase in the lumbar spine BMD
and ultimately lead to fracture (28, 29).
Studies exploring the association between BMD changes
and fracture reduction have been mainly conducted with
antiresorptive agents (30–32), but have yielded contradictory
results (12, 33–36). Amongwomen taking alendronate,Hoch-
berg et al. (25) found that larger increases in total hip and
spine BMD were associated with a lower risk of new verte-
bral fractures. However, another study using ameta-analytic
approach showed that the percentage reduction in vertebral
fracture risk attributable to increase in spine BMD after alen-
dronate treatment was only 16% (33). Moreover, it has re-
cently been shown that women losing BMD at the lumbar
spine (0–4%) while on alendronate still had a reduction in
vertebral fracture risk compared with their counterparts in
the placebo group (37). With raloxifene, increases in femoral
neck BMD after treatment account for only 4% of the effect
on vertebral fracture risk (34). More recently, increases in
lumbar spine and femoral neck BMD have been shown to
account for only 18% and 11%, respectively, of the effect of
risedronate on vertebral fracture incidence (24). However,
risedronate-treated patients whose BMD decreased were at
significantly greater risk of sustaining a vertebral fracture
than patients whose BMD increased. Meta-analytic ap-
proaches pooling different antiresorptive agents also pro-
duced conflicting results. Trials that reported larger increases
in BMD tended to observe greater reductions in vertebral
fracture risk (26). Using a Poisson regression, the model
predicts that treatments that increase spine BMD by 8%
would reduce risk of fracture by 54% and that most of the
total effect of treatment is explained by the increase in BMD
(26). Another meta-analysis has shown that the risk of non-
vertebral fractures decreased in patients with an increase in
BMD during treatment with antiresorptive agents (35). Re-
analysis of these data, however, using the same statistical
methods but correcting for discrepancies in the reported
BMD and person-year data, suggested that the magnitude of
the fracture risk reduction was not associated with the in-
crease in BMD (36). Thus, there is limited evidence to justify
use of the BMD increase during antiresorptive therapy as a
reliable indicator of fracture risk reduction (11, 12). Very few
studies have assessed the association between BMD changes
and fracture reductionwith bone-forming agents. To the best
of our knowledge, the only study dealing with this topic
found that an approximate 9–14% increase in spine BMD
after a treatment with teriparatide (i.e. 0.09 g/cm2 in women
with starting BMD 0.64–1.01) was associated with 30–41%
fracture risk reductions (38). This calculates to 3% risk re-
duction for every 1% increase in spinal BMD.
Because strontium is a heavier element than calcium, its
incorporation into bone influences BMD measurements (18,
19, 39). The combined effects of strontium distribution in
bone and increased x-ray absorption of strontium compared
with calcium leads to an amplification of BMDmeasurement
by DXA. These effects of strontium account for approxi-
mately 50% of the measured changes in BMD (10). However,
an algorithm for adjustment of BMD involves a number of
assumptions and cannot be used for individual patients (19).
In the present study, the association between BMD changes
and fracture incidence during 3-yr treatment with strontium
ranelate was obtained with unadjusted BMD values for
strontium because in daily practice the clinician will deal
with unadjusted BMD assessment.
Our study also showed that 1-yr changes in femoral neck
BMD were associated with future (3-yr) vertebral fracture
rates in patients treated with strontium. For each percentage
point increase in femoral neck BMD after 1 yr, the risk of
sustaining a new clinical vertebral fracture after 3 yr de-
creased by 3%. However, it should be acknowledged that the
95% CI (28) is quite wide. Anyway, these results are impor-
tant for monitoring strontium ranelate treatment because it
is then possible, after only 1 yr of treatment, to identify those
patients who will have the lowest risk of new vertebral frac-
tures over 3-yr treatment. Feedback of such results to the
patients could help increase treatment compliance, as re-
cently demonstrated (40). However, the exact impact ofmon-
itoring BMD on compliance needs to be assessed.
It should also be pointed out that some patients experi-
enced a decrease in BMD at 1 yr, but an increase in BMD at
3 yr. This reflects the principle of “regression to the mean”
(41). In our study population, 9.7% of the women experi-
enced a loss of spine BMD after 1 yr, but an increase after 3
Bruyere et al. • BMD Changes and Fracture Risk with Strontium Ranelate J Clin Endocrinol Metab, August 2007, 92(8):3076–3081 3079
 at Bibliotheque de la Faculte de Med - Univ De Liege on March 13, 2009 jcem.endojournals.orgDownloaded from 
yr. The same has been shown for femoral neck and total
proximal femur BMD (19.8 and 14.8% of patients, respec-
tively). These results confirm the data of Cummings et al. (41),
who showed that most women who lose BMD during the
first year of treatment with alendronate or raloxifene would
gain BMD if the same treatment were continued for a second
year. However, the value of changing or adding treatments
in women who persistently lose BMD has not been studied.
As previously discussed, the BMD changes accounted for
a substantial part of the vertebral antifracture efficacy of
strontium ranelate. However, BMD changes (in the spine but
also in the total proximal femur and femoral neck) do not
wholly explain the vertebral fracture efficacy of strontium
ranelate. The relationship between BMD changes and frac-
ture risk is confounded by other factors that contribute to the
etiology of vertebral fracture. One of these factors is the
change in bone microarchitecture during treatment with
strontium ranelate, which has been observed in rats (42). As
shown by animal studies, these positive effects on bone qual-
ity are also essential for antifracture efficacy (43). In three-
dimensional studies of bone microarchitecture in animals,
bone architecture contributes to vertebral strength over and
beyond the contributions of bone quantity (44). Even if they
are not exhaustively defined in the literature (36), these find-
ings could also account for the reduction in vertebral fracture
risk seen with strontium ranelate.
In our study, we failed to find statistically significant as-
sociations between 3-yr changes in BMD and the incidence
of new nonvertebral fractures, although a trend was found
for femoral neck BMD and for total proximal femur BMD. In
strontium ranelate-treated patients, the association between
changes in BMD and fracture risk reduction seems to be
stronger for vertebral fractures than for nonvertebral frac-
tures. It could be hypothesized that other factors, such as
falls, have a substantial influence on this relationship.
Despite their homogeneity, some of these findings should
be viewed cautiously. For each percentage point increase in
femoral neck BMD, the relative risk of new vertebral fracture
decreases by 3%. However, despite the large number of par-
ticipants in this trial, the 95% CI for this estimate is relatively
wide (between 1 and 5%). Our analysis was based on mea-
surement of BMD by DXA. It should be acknowledged that
imprecision in BMD measurement could modify the associ-
ation between BMD changes and fracture risk reduction. In
this particular study, BMD was assessed with strict quality
control (20).
In conclusion, the increase in BMD observed after 1 (fem-
oral neck) and 3 yr (femoral neck and total proximal femur)
was associated with a reduction in vertebral fracture inci-
dence during 3-yr treatment with strontium ranelate. This
relationship is of clinical relevance and may be of interest in
the monitoring of patients treated with strontium ranelate.
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